STILBENOID COMPOUNDS AS SILICA CELL CARCINOMA AND HEPATOMA INHIBITORS AND THEIR APPLICATION

摘要

1. The compound of formula I: or its stereoisomer, geometric isomer, tautomer, N-oxide, hydrate, solvate, metabolite or pharmaceutically acceptable salt or prodrug, where R ′, R are hydrogen or C1-6alkyl; R, R, R are each independently hydrogen , C1-6alkyl, or; R, R, R each independently represents hydrogen, C1-6alkyl, (CH) -CHOH or (CHOH) -CHOH, n = 0 to 3; and at least one of R, R, R is 2. A compound according to claim 1, characterized in that R, R, R each independently represents at least one of R, R, R is (CH) -CHOH, n = from 0 to 3.3. A compound according to claim 1, characterized in that R, R, R each independently represent at least one of R, R, R is (CHOH) -CHOH, n = from 0 to 3.4. A pharmaceutical composition containing a compound according to claim 1.5. The pharmaceutical composition of claim 4, further comprising a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, medium, or combinations thereof. A method for treating squamous cell carcinoma / hepatoma in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a compound according to claim 1.7. A process for preparing a compound of formula I, comprising deprotecting a compound of formula II: wherein R ′, R are hydrogen or C1-6alkyl; X, X, each independently are hydrogen, C1-6alkyl, or where R and R are each independently hydrogen or C1-6alkyl; X, X, Xne are selected from hydrogen and C1-6alkyl to give a compound of formula I: wherein R ′, R are hydrogen or C1-6alkyl; R, R, R are each independently hydrogen, C1-6alkyl, or; R, R, R are each independently